Pluristem Therapeutics develops placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries and hematologic conditions. Co.'s product candidates include: Placenta expanded (PLX)-peripheral arterial disease, which is used in recovery following surgery for hip fracture, in Acute Respiratory Distress Syndrome associated with COVID-19 and Intermittent Claudication, and used in for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease; and PLX-R18, which is used in incomplete hematopoietic recovery following hematopoietic cell transplantation and Acute Radiation Syndrome following or before exposure to massive radiation.